Anixa BiosciencesANIX +4.47%27 Net Debt Paydown Yield % is 0.03% as of Jul. 05, 2026, which is 200% above its 10-year median of 0.01. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,160 Biotechnology companies, Anixa Biosciences ranks better than 50.34% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Anixa Biosciences's Net Debt Paydown Yield % was 0.03%.
Anixa Biosciences (NAS:ANIX) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Anixa Biosciences Net Debt Paydown Yield % Related Terms
Anixa Biosciences Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANIX vs BMEA, PMN, ATRA: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Anixa Biosciences's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.03% mean?
Anixa Biosciences (ANIX) has a Net Debt Paydown Yield % of 0.03% as of Jul. 05, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Anixa Biosciences and its competitors. This is 200% above median its historical median of 0.01. According to the industry distribution chart, Anixa Biosciences ranks #576 out of 1160 companies in the Biotechnology industry, placing it in the top 49.7%.
Is Anixa Biosciences' Net Debt Paydown Yield % too high?
Anixa Biosciences' current Net Debt Paydown Yield % of 0.03% is 200% above median its 10-year median of 0.01. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Anixa Biosciences' value of 0.03% is 0% at this industry median. Based on the distribution chart, Anixa Biosciences ranks #576 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Net Debt Paydown Yield % compare to BMEA and PMN?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #576 out of 1160 companies for Net Debt Paydown Yield %. This puts Anixa Biosciences in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.03. Anixa Biosciences' value of 0.03% is 0% at this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.03, Anixa Biosciences has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anixa Biosciences's current Net Debt Paydown Yield % of 0.03% is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Anixa Biosciences and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anixa Biosciences's current Net Debt Paydown Yield % is 0.03%, which is 200% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Net Debt Paydown Yield % of 0.03%. The current Net Debt Paydown Yield % is 0.03%, which is 200% above median its 10-year median of 0.01 and 0% at the Biotechnology industry median of 0.03. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Net Debt Paydown Yield % is 0.03% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score
Get the complete analysis for ANIX
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
